Derik De Bruin
Stock Analyst at B of A Securities
(3.56)
# 691
Out of 5,182 analysts
206
Total ratings
64.08%
Success rate
13.5%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $21 → $30 | $22.43 | +33.75% | 10 | Apr 20, 2026 | |
| WAT Waters | Maintains: Neutral | $410 → $350 | $307.12 | +13.96% | 15 | Feb 10, 2026 | |
| BRKR Bruker | Maintains: Buy | $43 → $60 | $36.79 | +63.09% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $114.52 | +44.08% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,267.07 | +9.70% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $175.15 | +25.61% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $54.89 | -50.81% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $86.68 | +26.90% | 3 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $34.25 | +47.39% | 6 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $4.80 | +129.17% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $9.44 | +69.49% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $469.21 | +40.66% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $157.77 | +48.95% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $165.78 | +26.67% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $300.68 | +18.07% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $17.71 | +46.81% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $255.84 | +5.93% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $192.67 | -5.54% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $12.18 | +72.41% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $12.39 | +158.27% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $135.78 | -26.35% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.09 | +320.71% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.03 | +220.20% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $112.85 | +130.39% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $9.70 | +1,137.11% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $114.16 | +5.12% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.37 | +279.75% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $567.46 | -58.59% | 3 | Nov 2, 2018 |
10x Genomics
Apr 20, 2026
Maintains: Neutral
Price Target: $21 → $30
Current: $22.43
Upside: +33.75%
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $410 → $350
Current: $307.12
Upside: +13.96%
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $36.79
Upside: +63.09%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $114.52
Upside: +44.08%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,267.07
Upside: +9.70%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $175.15
Upside: +25.61%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $54.89
Upside: -50.81%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $86.68
Upside: +26.90%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $34.25
Upside: +47.39%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $4.80
Upside: +129.17%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $9.44
Upside: +69.49%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $469.21
Upside: +40.66%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $157.77
Upside: +48.95%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $165.78
Upside: +26.67%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $300.68
Upside: +18.07%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $17.71
Upside: +46.81%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $255.84
Upside: +5.93%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $192.67
Upside: -5.54%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $12.18
Upside: +72.41%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $12.39
Upside: +158.27%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $135.78
Upside: -26.35%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.09
Upside: +320.71%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.03
Upside: +220.20%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $112.85
Upside: +130.39%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $9.70
Upside: +1,137.11%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $114.16
Upside: +5.12%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.37
Upside: +279.75%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $567.46
Upside: -58.59%